Invesco’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.94M Buy
1,468,148
+35,137
+2% +$62.9K ﹤0.01% 2559
2025
Q4
$2.68M Buy
1,433,011
+326,238
+29% +$627K ﹤0.01% 2494
2025
Q3
$1.42M Buy
1,106,773
+267,433
+32% +$362K ﹤0.01% 2770
2025
Q2
$1.04M Buy
839,340
+314,697
+60% +$363K ﹤0.01% 2825
2025
Q1
$619K Buy
524,643
+263,067
+101% +$404K ﹤0.01% 3073
2024
Q4
$479K Buy
261,576
+1,004
+0.4% +$1.96K ﹤0.01% 3250
2024
Q3
$443K Buy
260,572
+6,718
+3% +$11K ﹤0.01% 3285
2024
Q2
$348K Buy
253,854
+11,121
+5% +$22.5K ﹤0.01% 3440
2024
Q1
$910K Buy
242,733
+40,741
+20% +$239K ﹤0.01% 3036
2023
Q4
$1.98M Sell
201,992
-904,860
-82% -$7.4M ﹤0.01% 2616
2023
Q3
$9.24M Sell
1,106,852
-74,137
-6% -$847K ﹤0.01% 1812
2023
Q2
$15.7M Buy
1,180,989
+993,369
+529% +$12.1M ﹤0.01% 1504
2023
Q1
$2.17M Sell
187,620
-127,861
-41% -$1.27M ﹤0.01% 2597
2022
Q4
$2.58M Buy
315,481
+203,011
+181% +$1.75M ﹤0.01% 2545
2022
Q3
$653K Sell
112,470
-3,521
-3% -$20.2K ﹤0.01% 3112
2022
Q2
$513K Buy
115,991
+4,708
+4% +$28.6K ﹤0.01% 3312
2022
Q1
$1.01M Sell
111,283
-3,084,507
-97% -$35.5M ﹤0.01% 3061
2021
Q4
$65.4M Buy
3,195,790
+3,103,297
+3,355% +$74.9M 0.02% 946
2021
Q3
$2.36M Buy
92,493
+11,198
+14% +$332K ﹤0.01% 2741
2021
Q2
$2.84M Sell
81,295
-1,100,243
-93% -$32M ﹤0.01% 2690
2021
Q1
$39.4M Sell
1,181,538
-516,070
-30% -$18.1M 0.01% 1173
2020
Q4
$44M Sell
1,697,608
-88,123
-5% -$1.5M 0.01% 1074
2020
Q3
$17.6M Buy
1,785,731
+1,737,939
+3,636% +$10M 0.01% 1369
2020
Q2
$165K Sell
47,792
-4,495
-9% -$15.3K ﹤0.01% 3525
2020
Q1
$160K Buy
+52,287
New +$214K ﹤0.01% 3467
2019
Q2
Sell
-19,195
Closed -$139K 3759
2019
Q1
$139K Buy
19,195
+1,204
+7% +$8.71K ﹤0.01% 3664
2018
Q4
$133K Sell
17,991
-4,463
-20% -$28.3K ﹤0.01% 3614
2018
Q3
$121K Buy
22,454
+4,475
+25% +$19.2K ﹤0.01% 3768
2018
Q2
$64K Sell
17,979
-40,556
-69% -$113K ﹤0.01% 3794
2018
Q1
$120K Sell
58,535
-4,118,416
-99% -$10.7M ﹤0.01% 3658
2017
Q4
$11M Sell
4,176,951
-1,006,412
-19% -$3.52M ﹤0.01% 1519
2017
Q3
$27.2M Sell
5,183,363
-16,778
-0.3% -$72.1K 0.01% 1043
2017
Q2
$18.5M Sell
5,200,141
-512
-0% -$2.06K 0.01% 1229
2017
Q1
$26.9M Sell
5,200,653
-122,553
-2% -$600K 0.01% 1050
2016
Q4
$20.2M Buy
5,323,206
+5,311,184
+44,179% +$38.6M 0.01% 1150
2016
Q3
$108K Sell
12,022
-90
-0.7% -$752 ﹤0.01% 3589
2016
Q2
$85K Sell
12,112
-241,695
-95% -$2.21M ﹤0.01% 3633
2016
Q1
$2.16M Buy
+253,807
New +$2.5M ﹤0.01% 2418
2015
Q3
Sell
-1,052
Closed -$6K 3934
2015
Q2
$6K Buy
+1,052
New +$6.09K ﹤0.01% 4127
2015
Q1
Sell
-186,862
Closed -$1.47M 4055
2014
Q4
$1.47M Buy
+186,862
New +$1.2M ﹤0.01% 2711
2014
Q3
Sell
-355,718
Closed -$2.2M 4114
2014
Q2
$2.2M Buy
355,718
+205,299
+136% +$1.03M ﹤0.01% 2522
2014
Q1
$805K Sell
150,419
-501,701
-77% -$3.17M ﹤0.01% 3158
2013
Q4
$3.41M Buy
652,120
+500,900
+331% +$2.3M ﹤0.01% 2286
2013
Q3
$835K Sell
151,220
-99,760
-40% -$346K ﹤0.01% 3130
2013
Q2
$635K Buy
+250,980
New +$625K ﹤0.01% 3163

Other funds holding PACB

Invesco's PACB Position: Q1 2026 in Review

Invesco increased its Pacific Biosciences (PACB) stake by 2.5% in Q1 2026, buying an estimated $62.9K and bringing the position to 1,468,148 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2559.

Invesco first reported a position in PACB in Q2 2013 and has held it in 45 quarters since. The position peaked at $65.4M in Q4 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Invesco held 1,468,148 shares of Pacific Biosciences worth $1.94M as of Q1 2026.
  • Invesco bought 35,137 Pacific Biosciences shares in Q1 2026, an estimated $62.9K.
  • Pacific Biosciences made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2559 holding.
  • Invesco first reported a position in Pacific Biosciences in Q2 2013 and has held it in 45 quarters since.
  • Invesco's Pacific Biosciences position peaked at $65.4M in Q4 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.